AbbVie Inc. is expected to report strong growth in its first quarter of fiscal 2026, with earnings per share projected at $2.93, a 19.1% increase year-over-year, and revenue forecasted at $14.72 billion, up 10.3%. The company’s dividend growth is also recovering, with a recent annual increase of 5.48%, suggesting stabilization after a period of slower growth. Key products Skyrizi and Rinvoq are helping offset declines from Humira, though competition from Johnson & Johnson’s Tremfya and Icotyde remains a risk to watch. These factors position AbbVie for a potential rebound in both profits and dividends moving forward.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
